Journal profile · Oncology
Current Cancer Drug Targets
ISSN 1568-0096 · eISSN 1873-5576 · Bentham Science Publishers B.V. · NETHERLANDS · Bimonthly · Founded 2001
Current Cancer Drug Targets: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.46; hybrid open access; median 91 days to acceptance (51 articles, last 24 months); community-reported acceptance: about 50%; 125 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Cancer Drug Targets is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Mechanisms and Therapy, Cancer, Hypoxia, and Metabolism and Cancer Research and Treatments, together about 17.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Mechanisms and TherapyMedicine6.1%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.8%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology5.7%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology5.2%
- Cancer Immunotherapy and BiomarkersMedicine4.6%
- Histone Deacetylase Inhibitors ResearchBiochemistry, Genetics and Molecular Biology4.5%
- Ferroptosis and cancer prognosisMedicine4.4%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.46LetPub ·
- CiteScore 2026-06
- 4.2LetPub ·
- SJR 2026-06
- 0.73LetPub ·
- SNIP 2026-06
- 0.55LetPub ·
- h-index
- 85LetPub ·
- h-index
- 115OpenAlex ·
- i10-index
- 1,220OpenAlex ·
- 2-year mean citedness
- 1.96OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 8.03%LetPub ·
Volume
- Articles per year
- 132LetPub ·
Articles by year OpenAlex count · 2,126 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 109 | 1 | 10 |
| 2025 | 125 | 15 | 202 |
| 2024 | 143 | 10 | 528 |
| 2023 | 96 | 8 | 752 |
| 2022 | 105 | 13 | 1,049 |
| 2021 | 71 | 5 | 768 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
91 daysMedian, submission to acceptance · P25–P75 77 days – 111 days
- Acceptance to online
- median 166 days (51 articles)
- Submission to online
- median 274 days
- Sample
- 51 articles with submission and acceptance dates (358 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1568-0096
- Electronic ISSN
- 1873-5576
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Cancer Drug Targets
What CAS zone is Current Cancer Drug Targets in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Cancer Drug Targets is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Cancer Drug Targets?
The latest impact factor listed by LetPub is 2.46; CiteScore 4.2, h-index 115.
How long does peer review take at Current Cancer Drug Targets?
Based on the dates recorded on 51 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 91 days (interquartile range 77–111 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Cancer Drug Targets?
According to LetPub and DOAJ records, Current Cancer Drug Targets is indexed in SCIE and Scopus.
Is Current Cancer Drug Targets open access, and what is the APC?
Current Cancer Drug Targets is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .